Autoimmune lymphoproliferative syndrome-like disease with somatic KRAS mutation

Blood

Volumn 117, Issue 10, 2011, Pages 2887-2890

  Takagi, Masatoshi ^a   Shinoda, Kunihiro ^b   Piao, Jinhua ^a   Mitsuiki, Noriko ^a   Takagi, Mari ^b   Matsuda, Kazuyuki ^c   Muramatsu, Hideki ^d   Doisaki, Sayoko ^d   Nagasawa, Masayuki ^a   Morio, Tomohiro ^a   Kasahara, Yoshihito ^e   Koike, Kenichi ^c   Kojima, Seiji ^d   Takao, Akira ^b   Mizutani, Shuki ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b Gifu Municipal Hospital   (Japan)

^c SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

K RAS PROTEIN; RAS PROTEIN;

APOPTOSIS; ARTICLE; AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; CASE REPORT; CHILDHOOD LEUKEMIA; CYTOPENIA; DIAGNOSTIC VALUE; FEMALE; HUMAN; INFANT; JUVENILE MYELOMONOCYTIC LEUKEMIA; LYMPHADENOPATHY; LYMPHOPROLIFERATIVE DISEASE; MALE; ONCOGENE K RAS; PRIORITY JOURNAL; SOMATIC MUTATION; SPLENOMEGALY;

EID: 79953124749     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-08-301515     Document Type: Article

References (19)

1. Fisher GH, Rosenberg FJ, Straus SE, et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell. 1995;81(6):935-946.
2. Teachey DT, Seif AE, Grupp SA. Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS). Br J Haematol. 2010;148(2):205-216.
3. Oliveira JB, Bidere N, Niemela JE, et al. NRAS mutation causes a human autoimmune lymphoproliferative syndrome. Proc Natl Acad Sci U S A. 2007;104(21):8953-8958. (Pubitemid 47175418)
4. Oliveira J, Bleesing J, Dianzani U, et al. Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop. Blood. 2010;116(14):e35-e40.
5. Miyauchi J, Asada M, Sasaki M, Tsunematsu Y, Kojima S, Mizutani S. Mutations of the N-ras gene in juvenile chronic myelogenous leukemia. Blood. 1994;83(8):2248-2254. (Pubitemid 24112737)
6. Emanuel PD. Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. Leukemia. 2008;22(7):1335-1342.
7. Aoki Y, Niihori T, Narumi Y, Kure S, Matsubara Y. The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders. Hum Mutat. 2008;29(8):992-1006.
8. Kitahara M, Koike K, Kurokawa Y, et al. Lupus nephritis in juvenile myelomonocytic leukemia. Clin Nephrol. 1999;51(5):314-318. (Pubitemid 29219300)
9. Oliver JW, Farnsworth B, Tonk VS. Juvenile myelomonocytic leukemia in a child with Crohn disease. Cancer Genet Cytogenet. 2006;167(1):70-73.
10. Saif MW, Hopkins JL, Gore SD. Autoimmune phenomena in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Lymphoma. 2002;43(11):2083-2092. (Pubitemid 35174719)
11. Flotho C, Kratz CP, Bergstrasser E, et al. Genotype-phenotype correlation in cases of juvenile myelomonocytic leukemia with clonal RAS mutations. Blood. 2008;111(2):966-967.
12. Matsuda K, Shimada A, Yoshida N, et al. Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations. Blood. 2007;109(12):5477-5480. (Pubitemid 46890572)
13. Flotho C, Valcamonica S, Mach-Pascual S, et al. RAS mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML). Leukemia. 1999;13(1):32-37. (Pubitemid 29043714)
14. Matsuda K, Sakashita K, Taira C, et al. Quantitative assessment of PTPN11 or RAS mutations at the neonatal period and during the clinical course in patients with juvenile myelomonocytic leukaemia. Br J Haematol. 2010;148(4):593-599.
15. Imamura M, Imai C, Takachi T, Nemoto T, Tanaka A, Uchiyama M. Juvenile myelomonocytic leukemia with less aggressive clinical course and KRAS mutation. Pediatr Blood Cancer. 2008;51(4):569.
16. Zhang J, Wang J, Liu Y, et al. Oncogenic Kras-induced leukemogeneis: hematopoietic stem cells as the initial target and lineage-specific progenitors as the potential targets for final leukemic transformation. Blood. 2009;113(6):1304-1314.
17. Sabnis AJ, Cheung LS, Dail M, et al. Oncogenic Kras initiates leukemia in hematopoietic stem cells. PLoS Biol. 2009;7(3):0537-0548.
18. Teachey DT, Manno CS, Axsom KM, et al. Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS). Blood. 2005;105(6):2443-2448. (Pubitemid 40387044)
19. Seif AE, Manno CS, Sheen C, Grupp SA, Teachey DT. Identifying autoimmune lymphoproliferative syndrome in children with Evans syndrome: a multi-institutional study. Blood. 2010;115(11):2142-2145.